Immune characteristics distinguish patients with severe disease associated with SARS-CoV-2.

Authors:
Li X; Liu Y; Li J; Sun L; Yang J and 6 more

Journal:
Immunol Res

Publication Year: 2020

DOI:
10.1007/s12026-020-09156-2

PMCID:
PMC7521864

PMID:
32989677

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Immunol Res

Abbreviation: Immunol Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Autoinflammatory diseases and the kidney.
Hegazy MT; Fayed A; Nuzzolese R and 2 more (2023) - Transparency Score: 3/6
Circulating anti-hypothalamus antibodies in celiac patients: tissue transglutaminase friend or foe?
Iervasi E; Strangio A; Greco L and 2 more (2023) - Transparency Score: 3/6
COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case rep…
Syrmou V; Liaskos C; Ntavari N and 6 more (2023) - Transparency Score: 3/6
COVID-19 vaccines adverse events: potential molecular mechanisms.
Lamprinou M; Sachinidis A; Stamoula E and 2 more (2023) - Transparency Score: 2/6
Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis ba…
Huang X; Shentu H; He Y and 4 more (2023) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest The authors declare that they have no conflict of interest."

Evidence found in paper:

"Funding Emergency Science and Technology Project for COVID-19 of Jiangxi Province (No. 202011-2); Nanchang Science and Technology Bureau (No. 20203306)"

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025